Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Sodium hyaluronate

Related Products

Hot Products

Basic Information Post buying leads Suppliers
Name

Sodium hyaluronate

EINECS 232-678-0
CAS No. 9067-32-7 Density 1.78g/cm3
PSA 399.71000 LogP -8.49480
Solubility soluble in water Melting Point
Formula (C14H20NO11Na)n Boiling Point 791.6oC
Molecular Weight 799.63800 Flash Point 432.5oC
Transport Information Appearance solid
Safety 22-24/25 Risk Codes 36/37/38
Molecular Structure Molecular Structure of 9067-32-7 (Hyaluronicacid, sodium salt) Hazard Symbols B,Xi
Synonyms

Arthrease;Artz Dispo;Artzal;Bio Hyaluro 12;Chlamyhyaluronic acid sodium salt;Cystistat;FCH 121-S;FCH 200;FCH 248;FCH 60;FCH 80;FCH-SU;Fermatron;HA-F;HA-Q;HA-Q 1;HA-QA;Hyaluronate sodium inj;Hyaluronate sodium;HE-QSE;Healon;Healon (polysaccharide);Healon GV;Healon V;Hyalart;Hyalein;Hyalgan;Hyaluronsan HA-LQ;Hyaluronsan HA-LQ1;Hyaluronsan HA-LQH;Hyaluronsan HA-Q;Hyaluronsan HA-QSS;Hyaluronsan M 5070;Hyasol;Hyasol BT;Hyladerm;Khionat;NRD 101;Nidelon;Opegan;Orthovisc;Ostenil;Provisc;SI 4402;SL 1010;SLM 10;SPH;Sinovial;Sodium hyaluronate;Suvenyl;

 

Sodium hyaluronate Specification

Sodium hyaluronate is the sodium salt of hyaluronan. With the CAS NO. 9067-32-7, it is a visco-elastic polymer normally found in the aqueous and vitreous humour. It is also called Arthrease, Bio Hyaluro 12 , CCRIS 4127, Chlamyhyaluronic acid sodium salt. Sodium hyaluronate is a viscous solution consisting of a high molecular weight (500,000-730,000 daltons) fraction of purified natural sodium hyaluronate in buffered physiological sodium chloride. We should keep container tightly closed and keep container in a cool, well-ventilated area. Do not store above 8°C (46.4°F). Refrigerate. Store at tempertures from 2 - 8 °C.

Physical properties about Sodium hyaluronate are: (1)ACD/LogP: -1.131; (2)# of Rule of 5 Violations: 2; (3)ACD/LogD (pH 5.5): -3.85; (4)ACD/LogD (pH 7.4): -4.83; (5)ACD/BCF (pH 5.5): 1.00; (6)ACD/BCF (pH 7.4): 1.00; (7)ACD/KOC (pH 5.5): 1.00; (8)ACD/KOC (pH 7.4): 1.00; (9)#H bond acceptors: 12; (10)#H bond donors: 7; (11)#Freely Rotating Bonds: 10; (12)Flash Point: 432.5 °C; (13)Enthalpy of Vaporization: 131.19 kJ/mol; (14)Boiling Point: 791.6 °C at 760 mmHg; (15)Vapour Pressure: 5.77E-29 mmHg at 25°C

Uses of Sodium hyaluronate: Sodium hyaluronate is used as a viscosupplement, administered through a series of injections into the knee, increasing the viscosity of the synovial fluid, which helps lubricate, cushion and reduce pain in the joint. It is generally used as a last resort before surgery and provides symptomatic relief, by recovering the viscoelasticity of the articular fluid, and by stimulating new production from synovial fluid.

When you are using Sodium hyaluronate, please be cautious about it as the following:
1. Do not breathe dust;
2. Avoid contact with skin and eyes;
3. Wear suitable protective clothing, gloves and eye/face protection;
4. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice;
5. Take off immediately all contaminated clothing;

You can still convert the following datas into molecular structure:

(1)InChI=1S/C28H44N2O23.Na/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43;/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45);/q;+1/t7-,8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19-,20+,21+,22+,25-,26+,27-,28-;/m1./s1;
(2)InChIKey=YWIVKILSMZOHHF-QJZPQSOGSA-N;
(3)Smiles[Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@@H](O[C@@H]3O[C@@H]([C@@H](O)[C@@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@@H](O)[C@H]1O)C(O)=O;

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 subcutaneous > 50mg/kg (50mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl,
mouse LD50 intraperitoneal 1500mg/kg (1500mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

SKIN AND APPENDAGES (SKIN): HAIR: OTHER
Oyo Yakuri. Pharmacometrics. Vol. 28, Pg. 1013, 1984.
mouse LD50 oral > 2400mg/kg (2400mg/kg)   Drugs in Japan Vol. -, Pg. 849, 1990.
mouse LD50 subcutaneous > 4gm/kg (4000mg/kg) BEHAVIORAL: ATAXIA Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984.
rabbit LD50 intraperitoneal 1820mg/kg (1820mg/kg) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION

BLOOD: NORMOCYTIC ANEMIA
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984.
rabbit LD50 oral > 1gm/kg (1000mg/kg)   Drugs in Japan Vol. -, Pg. 849, 1990.
rabbit LD50 subcutaneous > 2gm/kg (2000mg/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984.
rabbit LD50 subcutaneous > 2gm/kg (2000mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984.
rat LD50 intraperitoneal 1770mg/kg (1770mg/kg) SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE

BLOOD: NORMOCYTIC ANEMIA
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984.
rat LD50 oral > 800mg/kg (800mg/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984.
rat LD50 subcutaneous > 4gm/kg (4000mg/kg) BEHAVIORAL: ATAXIA Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984.

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields